October 2024 – Page 4

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

6 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management

6 months ago talkbio0Tagged abuse-deterrent, Approved, Opioids, Pain management, Protega Pharmaceuticals, Roxybond, SentryBond technology, United States Food and Drug Administration

FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

6 months ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns

Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance

6 months ago talkbio0Tagged Biopharma, Collaboration, molecular glue, Monte Rosa, Neoplasms, Neurological diseases, Novartis, Protein Degradation, Metabolic

Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases

Lilly and J&J Unveil Promising IL-23 Inhibitor Data for Crohn’s Disease, Setting Stage for FDA Decisions

6 months ago talkbio0Tagged Clinical Trials, Crohn 's disease, Decision, Eli, Eli Lilly, inhibitors, interleukin-23, Tremfya, United States Food and Drug Administration

Crohn’s disease, IL-23 inhibitors, Eli Lilly, Johnson & Johnson, Omvoh, Tremfya, clinical trials, FDA decisions.

FogPharma Rebrands to Parabilis Medicines, Emphasizing AI-Driven Drug Discovery

6 months ago talkbio0Tagged Aortic Valve Insufficiency, capabilities, Drug Discovery, FogPharma, Parabilis Medicines, rebranding

FogPharma, Parabilis Medicines, AI capabilities, drug discovery, rebranding

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

6 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition